Ablative Solutions today announced it completed the fourth tranche of its Series D financing round and raised $91.4 million.
Wakefield, Massachusetts-based Ablative Solutions earmarked the funds to complete the company’s ongoing Target BPI pivotal trial that is evaluating its alcohol-mediated renal denervation procedure.
Get the full story on our sister site, Medical Tubing + Extrusion.